

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG415 Epi-retinal brachytherapy for wet age-related macular degeneration

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

- | |
|--|
| 1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they? |
|--|

Age-related macular degeneration is patterned socio-demographically, particularly in relation to greater frequency in older age; and higher risk among past or current smokers.

- | |
|--|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified? |
|--|

There was no evidence of differential efficacy or safety of the procedure for different patient groups.

- | |
|--|
| 3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues? |
|--|

No

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Not applicable

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?

No

6. Have the Committee's considerations of equality issues been

described in the consultation document, and, if so, where?
Not applicable

Final interventional procedures document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?
Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

4. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?
Not applicable

Approved by Programme Director: Mirella Marlow

Date: 26 October 2011